

Gregory S Brigham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7731703/publications.pdf>

Version: 2024-02-01

34
papers

1,995
citations

304743

22
h-index

377865

34
g-index

35
all docs

35
docs citations

35
times ranked

2297
citing authors

#	ARTICLE	IF	CITATIONS
1	Disseminating evidence-based practices in substance abuse treatment: A review with suggestions. <i>Journal of Substance Abuse Treatment</i> , 2006, 31, 25-39.	2.8	348
2	Do Treatment Improvements in PTSD Severity Affect Substance Use Outcomes? A Secondary Analysis From a Randomized Clinical Trial in NIDA's Clinical Trials Network. <i>American Journal of Psychiatry</i> , 2010, 167, 95-101.	7.2	268
3	Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders.. <i>Journal of Consulting and Clinical Psychology</i> , 2009, 77, 607-619.	2.0	258
4	Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. <i>Addiction</i> , 2012, 107, 694-708.	3.3	184
5	Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment on Smoking Cessation Intervention in ADHD Smokers. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1680-1688.	2.2	78
6	Intervention with substance-abusing runaway adolescents and their families: Results of a randomized clinical trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2013, 81, 600-614.	2.0	54
7	Partnerships and pathways of dissemination: The National Institute on Drug Abuse's Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, S31-S43.	2.8	50
8	A Randomized Trial of Concurrent Smoking-Cessation and Substance Use Disorder Treatment in Stimulant-Dependent Smokers. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 336-343.	2.2	50
9	NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. <i>Contemporary Clinical Trials</i> , 2016, 50, 253-264.	1.8	49
10	Impulsivity is associated with treatment non-completion in cocaine- and methamphetamine-dependent patients but differs in nature as a function of stimulant-dependence diagnosis. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 541-547.	2.8	48
11	A randomized pilot clinical trial to evaluate the efficacy of Community Reinforcement and Family Training for Treatment Retention (CRAFT-T) for improving outcomes for patients completing opioid detoxification. <i>Drug and Alcohol Dependence</i> , 2014, 138, 240-243.	3.2	47
12	Multisite, Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial to Evaluate the Efficacy of Buspirone as a Relapse-Prevention Treatment for Cocaine Dependence. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 757-764.	2.2	47
13	Parenting under the influence: The effects of opioids, alcohol and cocaine on mother-child interaction. <i>Addictive Behaviors</i> , 2014, 39, 897-900.	3.0	46
14	From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, S53-S60.	2.8	45
15	Stimulant abuser groups to engage in 12-Step: A multisite trial in the National Institute on Drug Abuse Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 103-114.	2.8	44
16	Achieving Cannabis Cessation - Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. <i>Contemporary Clinical Trials</i> , 2014, 39, 211-223.	1.8	42
17	Helping Alliance, Retention, and Treatment Outcomes: A Secondary Analysis From the NIDA Clinical Trials Network Women and Trauma Study. <i>Substance Use and Misuse</i> , 2012, 47, 695-707.	1.4	33
18	Choosing a control group in effectiveness trials of behavioral drug abuse treatments. <i>Journal of Substance Abuse Treatment</i> , 2009, 37, 388-397.	2.8	31

#	ARTICLE	IF	CITATIONS
19	Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence. <i>Contemporary Clinical Trials</i> , 2016, 51, 34-43.	1.8	28
20	“Sub is a weird drug:” A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms. <i>American Journal on Addictions</i> , 2015, 24, 403-409.	1.4	27
21	Using buprenorphine short-term taper to facilitate early treatment engagement. <i>Journal of Substance Abuse Treatment</i> , 2007, 32, 349-356.	2.8	25
22	Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: Have we chosen the best designs?. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, S97-S112.	2.8	24
23	Decision-making processes as predictors of relapse and subsequent use in stimulant-dependent patients. <i>American Journal of Drug and Alcohol Abuse</i> , 2016, 42, 88-97.	2.1	23
24	Incentives for retention of pregnant substance users: A secondary analysis. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, 90-95.	2.8	20
25	Treating Nicotine Dependence by Targeting Attention-Deficit/ Hyperactivity Disorder (ADHD) With OROS Methylphenidate. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 983-990.	2.2	19
26	The potential impact of recruitment method on sample characteristics and treatment outcomes in a psychosocial trial for women with co-occurring substance use disorder and PTSD. <i>Drug and Alcohol Dependence</i> , 2012, 120, 225-228.	3.2	17
27	Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: An efficacy trial conducted in the real world. <i>Contemporary Clinical Trials</i> , 2012, 33, 993-1002.	1.8	16
28	How Practice and Science Are Balanced and Blended in the NIDA Clinical Trials Network: The Bidirectional Process in the Development of the STAGE-12 Protocol as an Example. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 408-416.	2.1	15
29	Design considerations for a study to evaluate the impact of smoking cessation treatment on stimulant use outcomes in stimulant-dependent individuals. <i>Contemporary Clinical Trials</i> , 2012, 33, 197-205.	1.8	14
30	Preliminary evaluation of a model of stimulant use, oxidative damage and executive dysfunction. <i>American Journal of Drug and Alcohol Abuse</i> , 2013, 39, 227-234.	2.1	13
31	A tale of two stimulants: Mentholated cigarettes may play a role in cocaine, but not methamphetamine, dependence. <i>Drug and Alcohol Dependence</i> , 2013, 133, 845-851.	3.2	13
32	An Exploration of Site Effects in a Multisite Trial of OROS-Methylphenidate for Smokers with Attention Deficit/Hyperactivity Disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 392-399.	2.1	9
33	Predictors of 12-Step Attendance and Participation for Individuals With Stimulant Use Disorders. <i>Journal of Substance Abuse Treatment</i> , 2016, 68, 74-82.	2.8	9
34	Community Reinforcement and Family Training for treatment retention and HIV behavioral risk reduction: A study protocol.. <i>Journal of Behavior Analysis in Health, Sports, Fitness and Medicine</i> , 2009, 2, 91-108.	0.2	1